HC Wainwright Forecasts Ardelyx’s Q3 Earnings (NASDAQ:ARDX)

Ardelyx, Inc. (NASDAQ:ARDX) – Research analysts at HC Wainwright reduced their Q3 2025 EPS estimates for shares of Ardelyx in a research note issued to investors on Friday, November 1st. HC Wainwright analyst E. Arce now anticipates that the biopharmaceutical company will post earnings per share of ($0.01) for the quarter, down from their prior estimate of $0.02. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Ardelyx’s Q4 2025 earnings at $0.01 EPS and FY2026 earnings at $0.58 EPS.

ARDX has been the topic of several other research reports. StockNews.com upgraded shares of Ardelyx from a “sell” rating to a “hold” rating in a research note on Wednesday, July 31st. Citigroup upped their price target on shares of Ardelyx from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Ardelyx in a research note on Friday, August 2nd. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.67.

Ardelyx Stock Up 3.7 %

ARDX stock opened at $6.09 on Monday. The business’s 50-day moving average is $6.07 and its two-hundred day moving average is $6.32. Ardelyx has a fifty-two week low of $3.43 and a fifty-two week high of $10.13. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.99 and a current ratio of 4.21. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -20.30 and a beta of 0.92.

Ardelyx (NASDAQ:ARDX) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.04. The company had revenue of $73.20 million for the quarter, compared to analysts’ expectations of $55.03 million. Ardelyx had a negative net margin of 28.82% and a negative return on equity of 46.86%. The firm’s quarterly revenue was up 228.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.08) earnings per share.

Insider Buying and Selling

In other Ardelyx news, CEO Michael Raab sold 25,000 shares of Ardelyx stock in a transaction on Monday, October 28th. The shares were sold at an average price of $5.91, for a total value of $147,750.00. Following the completion of the transaction, the chief executive officer now directly owns 1,210,108 shares of the company’s stock, valued at $7,151,738.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, insider David P. Rosenbaum sold 49,564 shares of the company’s stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $6.92, for a total transaction of $342,982.88. Following the transaction, the insider now directly owns 301,946 shares in the company, valued at approximately $2,089,466.32. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Michael Raab sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $5.91, for a total value of $147,750.00. Following the transaction, the chief executive officer now directly owns 1,210,108 shares in the company, valued at approximately $7,151,738.28. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 212,126 shares of company stock worth $1,298,963. Corporate insiders own 5.90% of the company’s stock.

Institutional Trading of Ardelyx

Several institutional investors and hedge funds have recently made changes to their positions in ARDX. Nisa Investment Advisors LLC boosted its position in Ardelyx by 1,026.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,548 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 3,233 shares during the period. Redwood Wealth Management Group LLC bought a new position in Ardelyx in the second quarter worth approximately $62,000. Coastal Bridge Advisors LLC purchased a new stake in Ardelyx during the second quarter worth $74,000. Helen Stephens Group LLC purchased a new stake in shares of Ardelyx during the 3rd quarter worth $76,000. Finally, Paloma Partners Management Co purchased a new stake in shares of Ardelyx during the first quarter valued at about $86,000. 58.92% of the stock is currently owned by institutional investors.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.